Table 3. Correlation coefficients between sputum autoantibody levels and clinical parameters in COPD patients (adjusted by age).

Sputum autoantibodies	FEV1 (%predicted)			CAT			mMRC			Number of exacerbations in the previous year
	r	P		r	P		r	P		r	P
Anti-Sm	0.101	0.504		0.182	0.226		0.026	0.864		0.115	0.448
Anti-P0	–0.045	0.766		0.421	0.004		0.190	0.205		0.370	0.011
Anti-Ro/SSA	–0.005	0.973		0.338	0.022		0.191	0.203		0.382	0.009
Anti-La/SSB	0.021	0.888		–0.058	0.701		0.025	0.871		0.025	0.869
Anti-Scl70	–0.083	0.584		0.041	0.787		0.167	0.266		0.174	0.246
Anti-Jo1	–0.197	0.191		0.085	0.576		0.122	0.419		0.268	0.072
Anti-TPO	0.244	0.103		–0.118	0.435		–0.169	0.262		–0.182	0.227
Anti-MPO	–0.111	0.463		0.309	0.037		0.159	0.292		0.206	0.171
Anti-PR3	–0.303	0.041		0.291	0.050		0.237	0.113		0.304	0.040
Anti-U1-SnRNP	–0.006	0.969		0.352	0.016		0.157	0.298		0.367	0.012

COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; CAT, COPD assessment test; mMRC, modified Medical Research Council Dyspnea Scale; Sm, Smith antigen; P0, ribosomal phosphoprotein P0; Ro/SSA, Ro/Sjögren syndrome type A antigen; La/SSB, La/Sjögren syndrome type B antigen; Scl-70, DNA topoisomerase I; Jo-1, histidyl-tRNA synthetase; U1-SnRNP, U1 small nuclear ribonucleoprotein; TPO, thyroid peroxidase; PR-3, proteinase-3; MPO, myeloperoxidase.